Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M, Haddad H, Leblanc MH, Giannetti N, Pflugfelder P, Davies R, Isaac D, Burton J, Chan M, Azevedo E, Howlett J, Ignaszewski A, Busque S, Cantarovich M, Ferguson R, Genest J, Ross H. White M, et al. Among authors: haddad h. J Heart Lung Transplant. 2005 Jul;24(7):798-809. doi: 10.1016/j.healun.2004.05.023. J Heart Lung Transplant. 2005. PMID: 15982605 Clinical Trial.
Cardiac signaling molecules and plasma biomarkers after cardiac transplantation: impact of tacrolimus versus cyclosporine.
White M, Cantin B, Haddad H, Kobashigawa JA, Ross H, Carrier M, Pflugfelder PW, Isaac D, Cecere R, Whittom L, Ali IS, Wang SH, He Y, Groulx A, Touyz RM. White M, et al. Among authors: haddad h. J Heart Lung Transplant. 2013 Dec;32(12):1222-32. doi: 10.1016/j.healun.2013.09.010. J Heart Lung Transplant. 2013. PMID: 24263023 Clinical Trial.
Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR; CADENCE Study Group. Ross H, et al. Among authors: haddad h. J Heart Lung Transplant. 2008 Feb;27(2):197-202. doi: 10.1016/j.healun.2007.11.565. J Heart Lung Transplant. 2008. PMID: 18267227 Clinical Trial.
Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
Cantarovich M, Ross H, Arizón JM, Gómez MA, Straatman L, Orús J, Alonso-Pulpón L, Molina BD, Wang S, Lage E, Crespo MG, Manito N, Howlett J, Haddad H; Motown Study Group. Cantarovich M, et al. Among authors: haddad h. Transplantation. 2008 Apr 15;85(7):992-9. doi: 10.1097/TP.0b013e318169bf43. Transplantation. 2008. PMID: 18408580 Clinical Trial.
Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study.
Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR; CADENCE Study Group (CAnadian Pilot Sutdy to Determine Safe and Effective Dosing of Neoral and CErtican in Stable Cardiac Transplant Recipients). Ross H, et al. Among authors: haddad h. Transpl Int. 2010 Jan;23(1):31-7. doi: 10.1111/j.1432-2277.2009.00940.x. Transpl Int. 2010. PMID: 20050127 Free article. Clinical Trial.
Neuroendocrine profiling of humans receiving cardiac allografts.
Ogawa T, Veinot JP, Davies RA, Haddad H, Smith SJ, Masters RG, Hendry PJ, Starling R, de Bold MK, Ponce A, Ma KK, Williams K, de Bold AJ. Ogawa T, et al. Among authors: haddad h. J Heart Lung Transplant. 2005 Aug;24(8):1046-54. doi: 10.1016/j.healun.2004.06.023. J Heart Lung Transplant. 2005. PMID: 16102440
533 results